This activity is expired and is no longer available for CME credit.


How Safe and Effective is Ranibizumab in AMD after 7 Years?

Author(s)/Faculty: Robert B. Bhisitkul, MD
Release Date: 6/1/2012Expiration Date: 5/31/2015
Credit Type: CME / ParticipationNumber of Credits: 0
Content Type: Provider:
This cohort, representing some of the earliest patients treated with intravitreal RZB, showed distinct outcome categories 7 to 8 years after initiation of RZB treatment ANCHOR or MARINA and in HORIZON. A minority of study eyes had excellent visual outcomes, while a majority have poor visual outcomes and ongoing AMD disease activity requiring treatment. With RZB therapy for exudative AMD, clinical vigilance and prolonged treatment may be required in some patients for 7 years or longer...